Serving Emerging Biotechnology Companies
Clinical Support
- Indication evaluation & selection
- Competitive landscape, TPP, value proposition and required clinical evidence package.
- Integrated strategic development strategy aligned with corporate objectives
- Clinical study design with critical value inflection points, including estimated time, cost & POS
- Regulatory strategy and meeting support
Corporate Support
- 3rd party capital raise by matching the sponsor's financial needs with our network of investors
- CRO selection, CRO management & oversight
- Out licensing and co-development
Serving Mid-Cap and Large Pharma
- Virtual development in the US for assets originating in Asia/Pac
- Virtual development in therapeutic areas outside the current corporate focus
- Monetize deprioritized assets
- Enable sponsors to focus on core priorities while maximizing portfolio value.
Serving Investors
Pre-investment
- BCC employs a holistic approach to evaluate the sponsor’s data package and provides an interpretation in the wider context of the proposed target product profile; current standard of care and unmet medical need; and the potential pathway to regulatory approval, reimbursement, and commercialization, or out-licensing. This includes estimates on time, cost, and PoS to reach value inflection points.
- BCC ensures that the clinical development strategy is focused on mitigating risk and value creation that can be financed in tranches as risk is mitigated. If risk is not mitigated, this results in a “fail fast / fail cheap” strategy.
Post-investment
- BCC can help manage/oversee investments by providing an objective assessment of the clinical development program including CRO/Vendor oversight to ensure efficient and effective capital spending focused on critical path clinical activities.
Services Emerging Biotechnolgy Companies
